News for Astellas Pharma Inc. (4503N.MX)

TOKYO, March 5, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children in Uganda, in an implementation science setting. This new pediatric treatment for schistosomiasis, developed by the GHIT-funded Pediatric Praziquantel Consortium, is being introduced through the Consortium's ADOPT program, which focuses on integrating arpraziquantel into existing healthcare platforms in countries where schistosomiasis is prevalent. This achievement marks GHIT's first supported innovation to reach people in need since its establishment in 2013.

PR NewswireNORTHBROOK, Ill., Feb. 27, 2025 Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise

PR NewswireTOKYO, Feb. 12, 2025 IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President an

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ETCompany ParticipantsHiromitsu Ikeda - Chief Communications...

The following slide deck was published by Astellas Pharma Inc.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart Month was officially declared by President Lyndon B.

PR NewswireTOKYO, Jan. 8, 2025 TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ann

China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla

Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders

Japan stocks higher at close of trade; Nikkei 225 up 1.16%

PR NewswireNORTHBROOK, Ill., Dec. 5, 2024 "Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural cha

In the 1990s, much of Asia's growth was fueled by industrialization and leveraging low-cost labor. Now, it's exporting culture, ideas, tech, leadership.

PR NewswireSAN FRANCISCO, Nov. 20, 2024 SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") to

Japan stocks higher at close of trade; Nikkei 225 up 0.45%

**media[466205]**

Global Women’s Health Therapeutics Market to Grow at 4.05% CAGR from 2024-2032, Fueled by Increased Focus on Reproductive Health, Menopause, and Breast...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of...